A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Trial Profile

A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

Suspended
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Sodium cromoglicate (Primary) ; Sodium cromoglicate (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Sponsors AZTherapies
  • Most Recent Events

    • 04 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top